Lipid-lowering medication and risk of cancer

Journal of Clinical Epidemiology

Volumn 52, Issue 2, 1999, Pages 167-169

  Olsen, Jørgen H ^a   Johansen, Christoffer ^a   Sørensen, Henrik Toft ^b,c   McLaughlin, Joseph K ^d   Mellemkjær, Lene ^a   Steffensen, Flemming Hald ^e   Fraumeni Jr , Joseph F ^f  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b UNIVERSITY OF AARHUS   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cohort studies; Lipid lowering drugs; Neoplasms; Pharmacoepidemiology

Indexed keywords

ANTILIPEMIC AGENT;

ADULT; ARTICLE; CANCER; CANCER RISK; COHORT ANALYSIS; DENMARK; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; POPULATION RESEARCH; PRIORITY JOURNAL;

ANTILIPEMIC AGENTS; DENMARK; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; RISK;

EID: 0033013503     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(98)00147-4     Document Type: Article

References (24)

1. Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J. 308:1994;367-372.
2. Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian simvastatin survival study (4S) Lancet. 344:1994;1383-1389.
3. Shepherd J., Cobbe S.M., Ford I.et al. Prevention of coronary heart disease with pravastin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
4. Jacobs D.R., Muldoon M.F., Råstam L. Low blood cholesterol, nonillness mortality, and other non-atherosclerotic disease mortality. A search for causes and confounders. (Invited commentary) Am J Epidemiol. 141:1995;518-522.
5. Zureik M., Courbon D., Ducimetière P. Decline in serum total cholesterol and the risk of death from cancer. Epidemiology. 8:1997;137-143.
6. Sharp S.J., Pocock S.J. Time trends in serum cholesterol before cancer death. Epidemiology. 8:1997;132-136.
7. Vatten L.J., Foss O.P. Total serum cholesterol and triglycerides and risk of breast cancer. A prospective study of 24,329 Norwegian women Cancer Res. 50:1990;2341-2346.
8. Pekkanen J., Smith D. Should there be a moratorium on the use of cholesterol lowering drugs? Br Med J. 304:1992;431-434.
9. Kritchevsky S.B., Kritchevsky D. Serum cholesterol and cancer risk. An epidemiologic perspective Ann Rev Nutr. 12:1992;391-416.
10. Newman T., Huley S.H. Carcinogenicity of lipid-lowering drugs. JAMA. 275:1996;55-60.
11. Capellá D. Descriptive tools and analysis. Dukes M.N.G. Drug Utilization Studies. Methods and Uses:1993;WHO Regional Publications, Copenhagen, Denmark.
12. Nielsen GL, Sørensen HT, Zhou W, Steffensen FH, Olsen J. The Pharmaco-Epidemiologic Prescription Database of North Jutland. Int J Risk Safety Med 1997 (In press).
13. Sørensen H.T., Larsen B.O. A population-based Danish data resource with possible high validity in pharmaco-epidemiological research. J Med Syst. 18:1994;33-38.
14. Jensen O.M. Cancer Morbidity and Causes of Death among Danish Brewery Workers. 1980;International Agency for Research on Cancer, Lyon.
15. Jensen O.M., Storm H.H., Jensen H.S. Cancer registration in Denmark and the study of multiple primary cancers, 1943-1980. Natl Cancer Inst Monogr. 68:1985;245-251.
16. Bailar J.C., Ederer F. Significance factors for the ratio of a Poisson variable to its expectation. Biometrics. 20:1964;639-643.
17. Cambien F., Ducimetière P. Richard JL. Total serum cholesterol and cancer mortality in middle-aged male population. Am J Epidemiol. 112:1980;388-394.
18. Sherwin R.W., Wentworth D.N., Cutler J.A., Hulley S.B., Kuller L.H., Stamler J. Serum cholesterol levels and cancer mortality in 361,622 men screened for the Multiple Risk Factor Intervention Trial. JAMA. 257:1987;2176-2180.
19. Jacobs D., Blackburn H., Higgins M.et al. Report of the conference on low blood cholesterol. Mortality associations Circulation. 86:1992;1046-1060.
20. Muldoon M.F., Manuck S.B., Matthews K.A. Lowering cholesterol concentration and mortality. A quantitative review of primary prevention trial Br Med J. 301:1990;309-314.
21. Law M.R., Thompson S.G., Wald N.J. Assessing possible hazards of reducing serum cholesterol. Br Med J. 308:1994;373-379.
22. Hebert P.R., Gaziano J.M., Chan K.S., Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 278:1997;313-321.
23. Sacks F.M., Pfeffer M.A., Moye L.A.et al. The effect of pravastin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
24. Olsen J.H., Sørensen H.T., Friis S.et al. Cancer risk in users of calcium channel blockers. Hypertension. 29:1997;1091-1094.